Novo Nordisk's (NVO) GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study, which has yet to be peer-reviewed, was published on medRxiv and supports findings reported in a Harvard University study from this past July.

Market Domination hosts Julie Hyman and Josh Lipton expand upon these findings and Novo Nordisk's year-to-date stock performance.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

This post was written by Luke Carberry Mogan.